Superworth

Cartesian Therapeutics profit margin RNAC

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
n/m
a quarter missing
Peer median
11.6%

Cartesian Therapeutics' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023n/an/a
FY202231.9%13.1%
FY2021−30.2%−5.4%
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/a−90.5%
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Cartesian Therapeutics' size, closest first, today.

CompanyProfit margin
RNACCartesian Therapeuticsn/m
NATRNatures Sunshine Products3.7%
LFVNLifevantage2.8%
ARVNArvinas2.9%
SPROSpero Therapeutics15.7%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
ATNMActinium Pharmaceuticalsn/m
COLLCollegium Pharmaceutical5.9%
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Cartesian Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.